News
As such, Novo Nordisk ended its collaboration with Hims & Hers over concerns of illegal mass compounding and deceptive ...
The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions ...
Novo Nordisk has ended a partnership with telehealth company Him & Hers, after launching the collaboration less than two ...
Stock markets have rallied after U.S. President Donald Trump announced a ceasefire in the Israel-Iran conflict, although the ...
Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...
In a statement, Novo Nordisk said that it was terminating the collaboration "due to concerns about their illegal mass ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results